| Gene Symbol |
GSK3A
|
| Entrez Gene |
2931
|
| Alt Symbol |
-
|
| Species |
Human
|
| Gene Type |
protein-coding
|
| Description |
glycogen synthase kinase 3 alpha
|
| Other Description |
GSK-3 alpha|glycogen synthase kinase-3 alpha|serine/threonine-protein kinase GSK3A
|
| Swissprots |
O14959 P49840
|
| Accessions |
AAD11986 EAW57114 EAW57115 P49840 BC027984 AAH27984 BC051865 AAH51865 CR749620 CAH18414 D63424 BAA23608 DQ891014 ABM81940 DQ893329 ABM84255 DQ894195 ABM85121 DQ896624 ABM87623 L40027 AAA62432 NM_019884 NP_063937
|
| Function |
Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), CTNNB1/beta-catenin, APC and AXIN1. Requires primed phosphorylation of the majority of its substrates. Contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. Regulates glycogen metabolism in liver, but not in muscle. May also mediate the development of insulin resistance by regulating activation of transcription factors. In Wnt signaling, regulates the level and transcriptional activity of nuclear CTNNB1/beta-catenin. Facilitates amyloid precursor protein (APP) processing and the generation of APP-derived amyloid plaques found in Alzheimer disease. May be involved in the regulation of replication in pancreatic beta-cells. Is necessary for the establish
|
| Top Pathways |
Chemokine signaling pathway, Dopaminergic synapse, Non-alcoholic fatty liver disease (NAFLD)
|